Prognostic Impact of Metastatic Sites in Patients with Biliary Tract Cancer Treated with Cisplatin, Gemcitabine, and Durvalumab - PubMed
3 hours ago
- #Prognostic Impact
- #Biliary Tract Cancer
- #Metastatic Sites
- Study evaluates the prognostic impact of metastatic sites in biliary tract cancer (BTC) patients treated with cisplatin, gemcitabine, and durvalumab (CGD).
- 666 patients (555 metastatic, 111 locally advanced BTC) were included; no significant prognostic impact of metastatic site location on overall survival (OS) was found.
- Patients with 1-2 metastatic sites had longer OS and progression-free survival (PFS) than those with 3-5 sites in univariate analysis, but not in multivariate analysis.
- No significant differences in OS or PFS were observed across different metastatic sites limited to a single organ.
- Change in metastatic sites after disease progression did not significantly affect OS2 (time from progression on first-line therapy to death).
- The study concludes no significant outcome differences based on metastatic site location or number in BTC patients treated with CGD.